We are a clinical-stage biopharmaceutical company exploring new ways to treat inflammatory and immune-related diseases.

Our goal is to transform the lives of patients suffering from acute and chronic diseases

Edesa’s monoclonal antibody candidates have been developed as host-directed therapeutics targeting immune dysregulation

Our drug candidates are designed to modulate pathways that are implicated across multiple immune-related diseases 

Late-stage drug candidates developed by Edesa Biotech aim to help patients with limited treatment options for inflammatory and immune-related diseases

Edesa Biotech is a clinical-stage biopharmaceutical company founded by experts in inflammatory and autoimmune diseases. We are exploring new ways to treat diseases, including alternatives to steroids and JAK inhibitors, which can have serious side-effects.

We prioritize our efforts on disease indications where there is compelling scientific rationale and where there are significant unmet medical needs, among other factors. We have multiple late-stage product candidates in our development pipeline in the fields of respiratory diseases and medical dermatology, including:
Vitiligo, an autoimmune disorder that causes the skin to lose its color in patches.
Allergic Contact Dermatitis, a common work-related skin condition.
Acute Respiratory Distress Syndrome, a life-threatening form of respiratory failure; and
Pulmonary Fibrosis,  a progressive lung disease that causes lung scarring and shortness of breath.

At the heart of Edesa’s corporate culture is an entrepreneurial spirit, and we are always building.  See our latest news releases for updates on these clinical programs and more.